Science News
from research organizations

New details of natural anticancer mechanism uncovered

Date:
June 11, 2013
Source:
Scripps Research Institute
Summary:
Scientists have identified key triggers of an important cancer-blocking mechanism in cells. Termed “oncogene-induced senescence,” this mechanism can block most cancer types and is commonly experienced when incipient skin cancers turn instead into slow-growing moles.
Share:
       
FULL STORY

Scientists at The Scripps Research Institute (TSRI) have identified key triggers of an important cancer-blocking mechanism in cells. Termed "oncogene-induced senescence," this mechanism can block most cancer types, and is commonly experienced when incipient skin cancers turn instead into slow-growing moles. Tumors that achieve malignancy often do so by defeating or circumventing this growth barrier -- which is why scientists have been eager to find out precisely how it works.

"We have known about some of the molecular signals that mediate this senescence response, but we've needed to understand the signaling pathway in much more detail," said Peiqing Sun, associate professor in TSRI's Department of Cell and Molecular Biology.

In the new study, published recently by the journal Molecular Cell, Sun and his colleagues describe the cascading interactions of three enzymes that are necessary to initiate a common type of oncogene-induced senescence.

Looking for Binding Partners

Oncogenes are growth-related genes that, through DNA damage, inherited mutations or some other cause, push cells to keep dividing beyond normal limits. Oncogenes in the ras gene family are the ones that have been most commonly linked to human cancers -- and most studied as triggers of senescence . Sun and other researchers showed a decade ago that an enzyme called p38 sits near the top of the ras-induced senescence response cascade. In 2007, Sun and his colleagues reported that p38 plays a role in this cascade by activating another enzyme, PRAK, through the addition of a phosphor group, a modification known as phosphorylation. For the new study, Sun and first author Research Associate Hui Zheng, along with other members of the laboratory, sought more details of PRAK's role in this cascade.

Zheng began the investigation by searching for binding partners of PRAK. With a series of protein-interaction assays he isolated an enzyme called Tip60, which binds tightly to PRAK. Further tests indicated that Tip60 does indeed lie within the senescence-inducing signaling cascade, because senescence fails to occur when Tip60 is absent.

PRAK is a kinase enzyme that, like p38, phosphorylates other proteins. Initially Zheng and Sun suspected that PRAK interacts with Tip60 by phosphorylating it, and thereby activating it.

Instead, the reverse turned out to be true: Tip60 acts on PRAK. Tip60 is a type of enzyme called an acetyltransferase, which modifies other proteins by adding acetyl groups. "Our tests showed that Tip60 binds to PRAK and acetylates it at a certain location, which helps activate PRAK," said Zheng.

Thus, the key enzyme PRAK requires two signals: "First the phosphorylation by p38 and then the acetylation by Tip60 are required for fully activating PRAK in this senescence-induction cascade," Zheng said.

Potential Cancer-Drug Strategy

What controls Tip60's own activation in this cascade? None other than the master switch, p38. "As a first step, p38 phosphorylates both Tip60 and PRAK," said Sun. Activated Tip60 then acetylates PRAK, completing PRAK's activation.

Previously Sun and his laboratory have shown that PRAK, when activated, goes on to activate the key tumor-suppressor protein p53, which exerts more direct control over a cell's growth machinery.

Sun and his team have been looking for ways to force the activation of the senescence response in cancer cells, as a potential cancer-drug strategy. "Finding these details of the early part of the signaling cascade helps us understand better what we need to target," he said.

Other contributors to the study, "A Posttranslational Modification Cascade Involving p38, Tip60 and PRAK Mediates Oncogene-Induced Senescence," were John Tat and Rong Liao of Sun's laboratory, and Xuemei Han, Aaron Aslanian and John R. Yates III of the Yates lab at TSRI.

The study was funded in part by the National Institutes of Health (grants CA106768 and CA131231).


Story Source:

The above story is based on materials provided by Scripps Research Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. Hui Zheng, Alim Seit-Nebi, Xuemei Han, Aaron Aslanian, John Tat, Rong Liao, John R. Yates, Peiqing Sun. A Posttranslational Modification Cascade Involving p38, Tip60, and PRAK Mediates Oncogene-Induced Senescence. Molecular Cell, 2013; 50 (5): 699 DOI: 10.1016/j.molcel.2013.04.013

Cite This Page:

Scripps Research Institute. "New details of natural anticancer mechanism uncovered." ScienceDaily. ScienceDaily, 11 June 2013. <www.sciencedaily.com/releases/2013/06/130611154044.htm>.
Scripps Research Institute. (2013, June 11). New details of natural anticancer mechanism uncovered. ScienceDaily. Retrieved May 27, 2015 from www.sciencedaily.com/releases/2013/06/130611154044.htm
Scripps Research Institute. "New details of natural anticancer mechanism uncovered." ScienceDaily. www.sciencedaily.com/releases/2013/06/130611154044.htm (accessed May 27, 2015).

Share This Page: